Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to give their consent to participate in the study
- People aged between 18 and 85 years old
- People who have had an irregular heart rhythm (atrial fibrillation) that has lasted more than 7 days but less than 2 years in total, as recorded in their medical notes
- People whose doctors are considering a procedure to restore their heart to a normal rhythm (cardioversion)
Who may not be able to join:
- People whose kidneys are not working well enough (below a certain level of kidney function)
- People who cannot take blood-thinning medications, either due to a medical reason or another factor preventing it
- People with high blood pressure that is not under control
- People for whom a catheter-based heart procedure would not be considered safe or suitable
- People with a body mass index (a measure of body weight relative to height) above 40
- People with this type of irregular heart rhythm who have already had more than one previous cardioversion procedure
- People who have been diagnosed with a specific inherited condition that causes the heart muscle to thicken abnormally (hypertrophic cardiomyopathy)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Richard Schilling, FRCP MD, Barts & The London NHS Trust
Phone: 02037658635
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recurrence of Persistent AF (AF episode lasting > 7 days) or left atrial ablation/ DC Cardioversion for atrial arrhythmia after 6 weeks of blanking period.; A change in the burden of AF, as measured by continuous monitoring through ILR (Implantable loop recorder) at 3 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.